Dapoxetine Treatment Has Fewer Side Effects in Men with Premature Ejaculation
World Meeting Travel Stipends: Apply by May 25
Men who take dapoxetine for premature ejaculation (PE) have low rates of treatment emergent adverse events (TEAEs), new research from Italy suggests.
Dapoxetine is a selective serotonin reuptake inhibitor (SSRI) that has been approved for PE treatment in over 60 countries. While the drug is considered safe, more research on TEAEs was warranted.
The study included 7,545 men from seven European countries. All of them had PE. Their average age was 41 years.
For 12 weeks, 6,128 men took at least one dose of dapoxetine while 1,417 took an alternative oral treatment (AOT).
TEAEs of special interest were more common in the AOT group. These included neurocognitive- and mood-related concerns as well as events in the urogenital/sexual function category.
Please click here for more information.
Fifteen travel stipends in the amount of USD 2,000 each are available for attendees of the 20th World Meeting on Sexual Medicine. The meeting will take place September 22-25, 2016 in Beijing, China.
Recipients will also receive free registration to the meeting. Allocation is based on need and applicants must meet specific criteria, including an abstract submission and written proof of a professional degree.
The application deadline is May 25, 2016. Complete details on the stipends may be found here.